Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

15 recruiting

Chronic Inflammatory Demyelinating Polyneuropathy Trials at a Glance

22 actively recruiting trials for chronic inflammatory demyelinating polyneuropathy are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 3 with 6 trials, with the heaviest enrollment activity in Houston, Copenhagen, and Washington D.C.. Lead sponsors running chronic inflammatory demyelinating polyneuropathy studies include argenx, CSL Behring, and Daishi Tian.

Browse chronic inflammatory demyelinating polyneuropathy trials by phase

Treatments under study

About Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials

Looking for clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy? There are currently 15 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Chronic Inflammatory Demyelinating Polyneuropathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Chronic Inflammatory Demyelinating Polyneuropathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 2

IMVT-1402 in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH162 enrolled135 locationsNCT07032662
Recruiting
Phase 3

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi160 enrolled115 locationsNCT06290141
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyCIDPCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx218 enrolled47 locationsNCT06920004
Recruiting
Phase 1

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

Myasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating Polyneuropathy
Kite, A Gilead Company52 enrolled3 locationsNCT07304154
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Chronic Inflammatory Demyelinating Polyneuropathy
Dianthus Therapeutics256 enrolled158 locationsNCT06858579
Recruiting
Phase 3

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
Kedrion S.p.A.161 enrolled2 locationsNCT06752356
Recruiting
Phase 1

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

Neuromyelitis Optica Spectrum Disorder (NMOSD)Multiple Sclerosis (MS)Myasthenia Gravis (MG)+3 more
Tongji Hospital6 enrolled1 locationNCT07526493
Recruiting
Not Applicable

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

Myasthenia GravisAmyotrophic Lateral SclerosisNeuromuscular Diseases (NMD)+15 more
University of Missouri-Columbia50 enrolled1 locationNCT07478172
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Chronic Inflammatory Demyelinating PolyneuropathyChronic Inflammatory Demyelinating PolyradiculoneuropathyCIDP
argenx160 enrolled19 locationsNCT07091630
Recruiting

Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices

CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Heinrich-Heine University, Duesseldorf35 enrolled2 locationsNCT07273903
Recruiting

Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Charcot-Marie-ToothCMT1A+2 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta39 enrolled1 locationNCT07461896
Recruiting

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Myasthenia GravisCIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx279 enrolled4 locationsNCT06299748
Recruiting
Early Phase 1

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Relapsing or Refractory Multiple Sclerosis (MS)Myasthenia Gravis (MG)Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)+1 more
Daishi Tian36 enrolled1 locationNCT07337785
Recruiting
Phase 1

IVIG vs SCIG in CIDP

Chronic Inflammatory Demyelinating PolyneuropathyCIDPImmunoglobulin Deficiency
Rutgers, The State University of New Jersey20 enrolled1 locationNCT05584631
Recruiting
Phase 4

Two Dose Levels of Privigen in Pediatric CIDP

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
CSL Behring30 enrolled9 locationsNCT03684018
Recruiting

Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Chronic Inflammatory Demyelinating Polyneuropathy
University of Ulm140 enrolled1 locationNCT07154524
Recruiting
Phase 2

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP

Chronic Inflammatory Demyelinating Polyneuropathy
Nuvig Therapeutics, Inc.60 enrolled1 locationNCT07027111
Recruiting
Phase 3

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
Octapharma30 enrolled6 locationsNCT04929236
Recruiting

Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study

POEMS SyndromeChronic Inflammatory Demyelinating Polyneuropathy (CIDP)Vasculitic Neuropathy
Rigshospitalet, Denmark520 enrolled1 locationNCT06040567
Recruiting

Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.

Chronic Inflammatory Demyelinating Polyneuropathy
Centre Hospitalier Universitaire de Liege40 enrolled1 locationNCT06183645